SenesTech (SNES) AI Stock Analysis

• Market Cap: $22.69M
• Dividend Yield: N/A
• Average Volume (3M): 96.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 36.89%
• EPS Growth: 91.74%
• Country: US
• Employees: 23
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): -0.87
• Shares Outstanding: 4,943,121
• 10 Day Avg. Volume: 104,576
• 30 Day Avg. Volume: 96,737
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.27
• Enterprise Value/Revenue: 2.90
• Enterprise Value/Gross Profit: 4.53
• Enterprise Value/Ebitda: -1.03
• 1Y Price Target: $7.25
• Price Target Upside: 56.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 51 Neutral
• Price Target: $4.50 ▼(-3.02% Downside)

SenesTech's overall stock score is driven by strong earnings call sentiment and revenue growth, but is tempered by ongoing profitability challenges and a weak valuation. The technical indicators suggest neutral momentum, while the lack of corporate events does not impact the score.

Positive Factors

Revenue Growth

The record revenue growth indicates strong market demand and successful product adoption, positioning SenesTech for continued expansion in its core markets.

Product Sales Expansion

The significant increase in Evolve product sales highlights the company's ability to innovate and capture market share, reinforcing its competitive position in pest management.

International Expansion

International agreements expand SenesTech's market reach, diversifying revenue streams and reducing reliance on domestic markets, which supports long-term growth.

Negative Factors

Profitability Challenges

Ongoing profitability issues, with negative EBIT and net income, could hinder SenesTech's ability to reinvest in growth and manage operational expenses effectively.

Cash Flow Struggles

Persistent negative cash flows indicate financial strain, potentially limiting SenesTech's ability to fund operations and strategic initiatives without external financing.

Decline in ContraPest Sales

The significant decline in ContraPest sales suggests challenges in maintaining product relevance and market share, which could impact overall revenue stability.

SenesTech Business Overview & Revenue Model

Company Description

SenesTech (SNES) is a biotechnology company focused on developing innovative solutions for pest management, particularly in the control of rat populations. The company operates in the agricultural and environmental sectors, providing products that utilize a novel technology aimed at reducing reliance on traditional rodenticides. Its core product, ContraPest, is designed to disrupt the reproductive cycle of rodents, leading to population control without the use of harmful chemicals.

How the Company Makes Money

SenesTech generates revenue primarily through the sale of its flagship product, ContraPest, to various markets including agriculture, food production, and urban pest control. The company employs a direct sales model alongside partnerships with pest control service providers and agricultural distributors to enhance product reach. Additional revenue streams may include licensing agreements for its technology and potential collaborations with governmental and environmental organizations focused on sustainable pest management solutions. The company's strategic partnerships with pest control professionals and agricultural entities further bolster its market presence and revenue potential.

SenesTech Financial Statement Overview

Summary

SenesTech shows potential with revenue growth and a stable balance sheet, but faces significant challenges in achieving profitability and positive cash flows. The company's financial health is hampered by ongoing net losses and negative cash flow, necessitating a strategic focus on operational efficiency and cost management to improve financial performance.

Income Statement

SenesTech has shown some revenue growth, with a significant increase from $1,193,000 in 2023 to $1,857,000 in 2024. However, the company is still struggling with profitability, as evidenced by the negative EBIT and net income. The gross profit margin has improved, but the net profit margin remains non-existent due to zero net income in 2024. These factors result in a moderate score, reflecting positive revenue trends but ongoing profitability challenges.

Balance Sheet

The balance sheet indicates a stable equity position with a decrease in total liabilities over the years. The debt-to-equity ratio is low, showing conservative leverage. However, the return on equity is weak due to persistent net losses, limiting the score to an average level. The company's financial stability is supported by a solid equity base, but profitability issues weigh heavily.

Cash Flow

SenesTech's cash flow statement reveals challenges with negative operating and free cash flows, despite some improvement in free cash flow from 2023 to 2024. The operating cash flow to net income ratio cannot be calculated for 2024 due to zero net income. The company has relied on financing activities to manage cash needs, reflecting ongoing cash flow struggles and reducing the score.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.09M	1.86M	1.19M	1.02M	576.00K	258.00K
Gross Profit	1.34M	1.00M	539.00K	464.00K	220.00K	-23.00K
EBITDA	-5.91M	-6.01M	-7.57M	-9.51M	-7.95M	-7.62M
Net Income	-4.43M	-6.18M	-7.71M	-9.71M	-8.27M	-7.94M
Balance Sheet
Total Assets	10.37M	3.28M	7.29M	6.78M	11.50M	6.02M
Cash, Cash Equivalents and Short-Term Investments	6.05M	1.31M	5.39M	4.78M	9.33M	3.64M
Total Debt	2.69M	262.00K	406.00K	359.00K	555.00K	1.44M
Total Liabilities	3.39M	767.00K	942.00K	1.50M	1.47M	2.14M
Stockholders Equity	6.98M	2.51M	6.35M	5.28M	10.04M	3.88M
Cash Flow
Free Cash Flow	-5.45M	-6.12M	-7.71M	-8.75M	-7.88M	-7.22M
Operating Cash Flow	-5.32M	-6.03M	-7.57M	-8.58M	-7.78M	-7.11M
Investing Cash Flow	-126.00K	-56.00K	-149.00K	-170.00K	-99.00K	-67.00K
Financing Cash Flow	9.53M	2.00M	8.34M	4.20M	13.56M	8.88M

SenesTech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.64
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNES, the sentiment is Positive. The current price of 4.64 is below the 20-day moving average (MA) of 4.83, below the 50-day MA of 4.93, and above the 200-day MA of 3.46, indicating a neutral trend. The MACD of -0.07 indicates Positive momentum. The RSI at 46.47 is Neutral, neither overbought nor oversold. The STOCH value of 21.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNES.

SenesTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FSI	72 Outperform	120.36M	40.76	7.73%	―	-1.52%	6.38%
NTIC	68 Neutral	73.90M	25.82	7.60%	2.05%	3.46%	-34.80%
LOOP	54 Neutral	75.39M	-5.65	488.80%	―	8400.76%	31.02%
SNES	51 Neutral	$22.69M	―	-119.89%	―	36.89%	91.74%
GURE	48 Neutral	8.12M	-0.24	―	―	-15.26%	73.10%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

SenesTech Corporate Events

SenesTech Enters New Warrant Agreements for Funding

On August 4, 2025, SenesTech entered into agreements with certain warrant holders to exercise existing warrants for 1,458,872 shares of common stock at $4.15 per share, generating gross proceeds of approximately $6.3 million. In return, the company will issue new short-term warrants for 2,188,308 shares at $5.25 per share, with the proceeds intended for working capital and general corporate purposes. The transactions, facilitated by H.C. Wainwright & Co., LLC, are expected to close around August 5, 2025, and include issuing placement agent warrants. The new warrants are unregistered and have a fifteen-month expiration post-registration statement effectiveness.

SenesTech Appoints Lynn Y. Graham to Board

On July 5, 2025, SenesTech‘s Board of Directors expanded to seven members, appointing Lynn Y. Graham as an independent Class III director until the 2028 Annual Meeting of Stockholders. Ms. Graham will also join the Board’s Commercialization Committee, with no prior arrangements influencing her selection and no related transactions under Regulation S-K.

SenesTech Raises $4.4M Through Warrant Exercise

On June 30, 2025, SenesTech entered into agreements with certain warrant holders for the exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share, generating gross proceeds of approximately $4.4 million. In exchange, SenesTech will issue new short-term warrants for the same number of shares at an exercise price of $4.15 per share, with potential additional proceeds of $6.0 million if fully exercised. The company plans to use the funds for working capital and general corporate purposes, with H.C. Wainwright acting as the exclusive placement agent for the transaction.

SenesTech Registers Additional Shares for Capital Raising

On June 30, 2025, SenesTech registered an additional $711,227 worth of common stock shares under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC. Prior to this, the company had sold $2,854,827.84 in shares through the same agreement, indicating ongoing efforts to raise capital.

SenesTech Stockholders Approve Key Proposals at Annual Meeting

On June 9, 2025, SenesTech held its Annual Meeting in Surprise, Arizona, where stockholders voted on several key proposals. The election of Class III directors, approval of executive compensation for fiscal 2024, ratification of M&K CPAS, PLLC as the accounting firm, and authorization of common stock issuance were among the approved items. However, the amendment to increase shares under the 2018 Plan was not approved. Additionally, stockholders approved a reverse stock split proposal to maintain Nasdaq listing and an adjournment proposal to allow further voting if necessary.